Medicinal cannabis hub
Information about access pathways for medicinal cannabis products.
The medicinal cannabis hub brings together information on the regulation of medicinal cannabis in Australia along with guidance material and information resources for consumers, health professionals and sponsors.
While we regulate the access, most medicinal cannabis products are considered to be unapproved medicines. Unapproved medicines have not been assessed by us for safety, quality or effectiveness.
However, where clinically appropriate, there are pathways for registered health care professionals to access medicinal cannabis products for their patients.
For completeness, the medicinal cannabis hub also contains information relating to cannabis vapes.
More information
- Applications and reporting
- Medicinal cannabis products by active ingredients
- Resources, clinical trials and clinical evidence
- Presentation: TGO93 testing and regulation of medicinal cannabis
Frequently asked questions
- Access to medicinal cannabis products
- Accessing medicinal cannabis for a patient
- Importation, manufacture and supply of unapproved medicinal cannabis products
Data
Reforms
- Webinar presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications, 22 November 2021
- Webinar presentation: Medicinal cannabis - Changes to sponsor requirements for supplying unapproved medicinal cannabis products in Australia, 22 November 2021
- Webinar presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications, 23 November 2021
- Webinar: Medicinal cannabis reforms
Latest articles
-
News Life Media fined for alleged unlawful advertising of medicinal cannabis
TGA has issued 3 infringement notices totalling $56,340 to News Life Media Pty Ltd for alleged unlawful advertising of medicinal cannabis on their popular lifestyle website Body+Soul. -
More than $600,000 in fines issued for alleged unlawful medicinal cannabis advertising
TGA has issued 35 infringement notices totalling $627,252 to 6 businesses and 2 individuals for the alleged unlawful advertising of medicinal cannabis on their websites and social media platforms. -
Better Leaf Pty Ltd fined for alleged unlawful advertising of medicinal cannabis
Infringement notices totalling $171,972 have been issued to Better Leaf Pty Ltd, and an individual, for the alleged unlawful advertising of medicinal cannabis on its website and social media.
Latest publications
-
Medicinal cannabis products are permitted to be supplied into Australia under the Special Access Scheme, by authorised prescribers, and/or for use in clinical trials.
-
This publication outlines our plan to transition to a paperless model for Special Access Scheme (SAS) and Authorised Prescriber (AP) submissions. From 1 July 2024 we will only accept submissions via the SAS/AP Online System.
-
Public notice of the delegate's final decision to amend the Poisons Standard in relation to cannabidiol (private application and delegate initiated) - Joint ACMS-ACCS #25 and #26 (June and November 2020).
Latest guidance
-
This guidance will help ensure you do not unlawfully advertise medicinal cannabis to consumers, if you give out information about medicinal cannabis or advertise health services.
-
Guidance for importation, supply and wholesale requirements for medicinal cannabis.
-
Guidance on specific criteria and paperwork required for submission to the TGA to ensure conformance with TGO 93.